{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:50:39Z","timestamp":1787500239064,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>OnabotulinumtoxinA (onabotA) is an approved treatment for overactive bladder (OAB). This chart review study aims to determine treatment persistence in patients receiving onabotA (100\u2009U) via a reduced injection\u2010site paradigm distributed across\u2009\u2264\u20093 injection sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a single site, noninterventional, retrospective chart review evaluating adult female OAB patients refractory to behavioral modification and pharmacotherapy before receiving\u2009\u2265\u20091 treatment with onabotA (100\u2009U) via 1\u22123 injections between July 2017 and June 2021. Patients with neurologic OAB, predominance of stress incontinence, or who expired during the study were excluded. Baseline demographics, treatment patterns, treatment persistence, treatment intervals, lidocaine pretreatment, patient\u2010reported treatment response, and adverse urological events were documented and evaluated. Persistence was defined as the percent of patients receiving\u2009\u2265\u20093 treatments during the study period via three or fewer injections. Continuous variables were summarized with sample size, mean (standard deviation [SD]), and median (1st and 3rd quartiles); categorical variables were calculated as frequencies and percentages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 90 patients included in this study, 55 (61.1%) were persistent to treatment with onabotA for OAB, completing 3 treatments by the end of the data collection period. Urinary tract infection (UTI) was reported after 18\/370 (4.9%) treatments. Of 90 patients,15 (16.7%) reported UTI after any treatment, and none required clean intermittent catheterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>When onabotA was administered via a reduced injection\u2010site paradigm, 61.1% of patients were persistent to OAB treatment. Given the limited pool of patients included in this study and relatively low sample sizes at later timepoints, results may not be generalizable. No new safety signals were identified using the reduced injection\u2010site paradigm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>Due to the nature of this study, no clinical trial registration was required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.25634","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:46:07Z","timestamp":1733895967000},"page":"338-344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient Persistence to OnabotulinumtoxinA Treatment for Overactive Bladder Using a Reduced Injection\u2010Site Paradigm: A Retrospective Chart Review Study"],"prefix":"10.1002","volume":"44","author":[{"given":"Steven","family":"Bernstein","sequence":"first","affiliation":[{"name":"Fairview Urology Fridley Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-751X","authenticated-orcid":false,"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[{"name":"MS Biostatistics, LLC Clermont Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5303-7992","authenticated-orcid":false,"given":"Kimberly Becker","family":"Ifantides","sequence":"additional","affiliation":[{"name":"Medical Affairs AbbVie Inc. North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107368"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20798"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.07.1325"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003985"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0216-4"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0600-9"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12151"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2016.12.030"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13558"},{"key":"e_1_2_12_11_1","unstructured":"\u201cAllergan \u201d Inc. BOTOX (onabotulinumtoxinA) Label accessed September 13 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103000s5327lbl.pdf."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25370"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25290"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-008-0362-0"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22780"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25107"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.046"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23052"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.03.146"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.069"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T05:19:19Z","timestamp":1738559959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.25634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/nau.25634"],"URL":"https:\/\/doi.org\/10.1002\/nau.25634","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"2024-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}